跳至主要内容
临床试验/NCT00367614
NCT00367614已完成3 期

A Multicenter, Randomized, Open-Label, Single And Multiple Dose Study Of The Pharmacokinetics And Safety of Two Dose Levels of Pantoprazole Sodium Tablets In Adolescents Aged 12 Through 16 Years With A Clinical Daignosis Of GERD.

Wyeth is now a wholly owned subsidiary of Pfizer0 个研究点目标入组 20 人开始时间: 2007年1月1日最近更新:
适应症
相关药物

试验速览

阶段
3 期
状态
已完成
发起方
入组人数
20
主要终点
Characterization of the PK profile of single and multiple doses of pantoprazole.

研究概览

简要总结

The purpose of this study is characterize the PK profile of single and multiple doses of pantoprazole in adolescents aged 12 to 16 years with Gastroesophageal Reflux Disease (GERD).

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
12 Years 至 16 Years(Child)
性别
All
接受健康志愿者
否

入选标准

  • •12-16 years old
  • •clinical diagnosis of GERD
  • •ability to swallow tablets

排除标准

  • •GI or malabsorption disorders
  • •chronic use of warfarin
  • •positive pregnancy test

结局指标

主要结局

Characterization of the PK profile of single and multiple doses of pantoprazole.

次要结局

  • Assess the safety and tolerability of pantoprazole.

研究者

发起方
Wyeth is now a wholly owned subsidiary of Pfizer
申办方类型
Industry

相似试验